Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Dr Kopetz on the Rationale of the BREAKWATER Study in BRAF V600E­mutant mCRC

May 4th 2023

Scott Kopetz, MD, PhD, FACP, discusses the rationale for launching the phase 3 BREAKWATER trial in BRAF V600E­–mutant metastatic colorectal cancer.

Dr Bloomer on HRQOL Outcomes in Younger and Older Patients in CRC

May 3rd 2023

Amanda Bloomer, PhD, discusses the comparison of health-related quality of life outcomes between younger and older adult patients with newly diagnosed colorectal cancer evaluated in the ColoCare study.

IMX-110 Plus Tislelizumab Shows Early Activity in Advanced Metastatic Colorectal Cancer

May 3rd 2023

Treatment with the combination of IMX-110 and tislelizumab resulted in 100% tumor shrinkage at 2 months in 2 of 2 evaluable patients with advanced metastatic colorectal cancer who received the regimen at the lowest dose level examined in the dose-escalation portion of the ongoing phase 1b/2a IMMINENT-01 trial

Dr Hays on the Significance of the Tucatinib/Trastuzumab Approval in HER2-Positive mCRC

May 3rd 2023

John L. Hays, MD, PhD, discusses the significance of the approval for tucatinib and trastuzumab for patients with HER2-expressing metastatic colorectal cancer.

Understanding Lynch Syndrome and Associated Cancer Risk: Prevalence

May 3rd 2023

In this first episode of OncChats: Understanding Lynch Syndrome and Cancer Risk, Fay Kastrinos, MD, MPH, provides a brief overview of Lynch syndrome and its prevalence in the United States and beyond.

Dr Murciano-Goroff on the Investigation of KRAS G12C Inhibitor LY3537982 in Solid Tumors

April 28th 2023

Yonina R. Murciano-Goroff, MD, MSc, DPhil, discusses the investigation of the novel KRAS G12C inhibitor LY3537982 in patients with non–small cell lung cancer, colorectal cancer, and other solid tumors.

Evolutions in the HER2-Amplified CRC Treatment Landscape

April 28th 2023

Looking toward the future management of HER2-amplified colorectal cancer, panelists reflect on ongoing clinical trials and evolving treatment strategies.

Phase IB Study of GDC-6036 in Combination with Cetuximab in Patients With Colorectal Cancer (CRC) With KRAS G12C Mutation

April 28th 2023

Jayesh Desai, MBBS, FRACP, shares data from a phase IB study investigating KRAS G12C inhibitor GDC-6036, or divarasib, in combination with cetuximab for the treatment of patients with colorectal cancer.

Real-World Use of HER2-Directed Therapies in Colorectal Cancers

April 28th 2023

Expert perspectives on the real-world use of HER2-directed therapies in patients with HER2-amplified colorectal cancer.

Tucatinib/Trastuzumab Approval Highlights Expansion of Tailored Therapies in HER2+ CRC

April 21st 2023

John L. Hays, MD, PhD, discusses the importance of tailoring therapies for patients with CRC who express HER2 or have other actionable targets, the need to develop optimal sequences for local and systemic therapy in CRC, and key updates in hepatocellular carcinoma and pancreatic cancer.

HER2-Amplified Colorectal Cancer: Clinical Trial Data

April 21st 2023

A focused discussion on HER2-amplified colorectal cancer and respective clinical trials that inform use of targeted agents in this setting.

Treatment Algorithm for Metastatic Colorectal Cancer

April 21st 2023

Broadening their conversation, expert oncologists define the treatment algorithm for patients diagnosed with colorectal cancer.

FDA Grants Fast Track Designation to Botensilimab Plus Balstilimab in Non–MSI-H/dMMR mCRC

April 20th 2023

The FDA has granted a fast track designation to the combination of botensilimab plus balstilimab for the treatment of patients with non–microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer with no active liver involvement.

Novel Detection Methods May End Chemotherapy for Patients With CRC

April 19th 2023

A new genetic test that may allow patients with colorectal cancer to avoid chemotherapy after tumor resection is under investigation at AdventHealth Cancer Institute in Orlando, Florida.

FDA Grants Priority Review to TAS-102 Plus Bevacizumab for Refractory mCRC

April 18th 2023

The FDA has accepted for priority review the supplemental new drug application seeking the approval of trifluridine/tipiracil as a single agent or in combination with bevacizumab for use in select patients with refractory, metastatic colorectal cancer.

Divarasib Plus Cetuximab Demonstrates Promising Clinical Activity and Manageable Safety in KRAS G12C–Mutant CRC

April 18th 2023

The selective, oral KRASG12C inhibitor divarasib demonstrated promising clinical activity in patients with colorectal cancer treated with the agent plus cetuximab.

African Ancestry Is Associated With Fewer Actionable Alterations in CRC

April 17th 2023

Patients with African ancestry with colorectal cancer have fewer actionable gene mutations than those with European ancestry, leading to fewer targeted treatment options in this population.

MOUNTAINEER and DESTINY-CRC01 Trials Expand Second-Line Options for HER2+ mCRC

April 15th 2023

Alaa Muslimani, MD, discusses the significance of the phase 2 DESTINY-CRC01 and MOUNTAINEER-03 trials on HER2-positive metastatic colorectal cancer treatment in the second line, efforts to expand the use of these agents in earlier disease settings, and the need for more robust clinical data and larger investigations for this population.

Role of Circulating Tumor DNA Testing in Colorectal Cancer

April 14th 2023

In the context of colorectal cancer clinical trials, panelists reflect on the role of liquid biopsies to help inform treatment decisionmaking.

Role of HER2 Expression in Colorectal Cancer

April 14th 2023

A brief review of HER2 amplification and how it may impact the treatment pathway for patients with a diagnosis of colorectal cancer.

NEXT PAGE
PREVIOUS PAGE